{"schema_version":"secwatch.filing_event.v1","accession":"0001711279-23-000039","form_type":"8-K","ticker":"KRYS","cik":"0001711279","company_name":"Krystal Biotech, Inc.","filed_at":"2023-05-22T23:59:59+00:00","discovered_at":"2026-05-14T18:03:40.163335+00:00","generated_at":"2026-06-14T18:20:16.568061+00:00","sec_items":["1.01","3.02","7.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Krystal Biotech raises $160M in PIPE at $92.50/share for VYJUVEK launch and pipeline","bullets":["Sold 1,729,729 shares at $92.50 each to institutional investors; gross proceeds ~$160M.","PIPE led by Avoro Capital Advisors and Redmile Group, with Braidwell LP and Frazier Life Sciences.","Proceeds to fund VYJUVEK commercialization, clinical pipeline, business development, and working capital.","Company expects to fund operations through end of 2026; retains optionality on Priority Review Voucher.","Registration statement for resale of shares to be filed within 60 days of closing."],"urls":{"canonical":"https://secwatch.observer/filing/0001711279-23-000039","json":"https://secwatch.observer/filing/0001711279-23-000039.json","markdown":"https://secwatch.observer/filing/0001711279-23-000039.md","text":"https://secwatch.observer/filing/0001711279-23-000039.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1711279/000171127923000039/0001711279-23-000039-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1711279/000171127923000039/krys-20230522.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-14T18:20:16.568061+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"82a2fdb36ed9e599e68876a0bf8b22e9639e1b26","claim":"Krystal Biotech, Inc. entered into Securities Purchase Agreement with certain institutional investors valued at approximately $160 million (effective 2023-05-21).","evidence_excerpt":"On May 21, 2023, Krystal Biotech, Inc. (the “Company”) entered into a Securities Purchase Agreement (the “Purchase Agreement”) with certain institutional investors (collectively, the “Investors”) to issue and sell at closing an aggregate of 1,729,729 shares of common stock of the Company, par value $0.00001 per share (the “Common Stock”), at a price of $92.50 per share for an aggregate purchase price of approximately $160 million (the “Investment”).","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1711279/000171127923000039/0001711279-23-000039-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"equity purchase"},{"label":"Counterparty","value":"certain institutional investors"},{"label":"Value","value":"approximately $160 million"},{"label":"Effective","value":"2023-05-21"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}